Tacrolimus as prophylaxis for acute graft-versus-host disease in reduced intensity cord blood transplantation for adult patients with advanced hematologic diseases

Transplantation

Volumn 84, Issue 3, 2007, Pages 316-322

  Miyakoshi, Shigesaburo ^a   Kami, Masahiro ^b   Tanimoto, Tetsuya ^c   Yamaguchi, Takuhiro ^b   Narimatsu, Hiroto ^a   Kusumi, Eiji ^a   Matsumura, Tomoko ^b   Takagi, Shinsuke ^a   Kato, Daisuke ^a   Kishi, Yukiko ^a   Murashige, Naoko ^d   Yuji, Koichiro ^a   Uchida, Naoyuki ^a   Masuoka, Kazuhiro ^a   Wake, Atsushi ^a   Taniguchi, Shuichi ^a  

^a TORANOMON HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

^d Japan Ministry of Health Labour and Welfare   (Japan)

Author keywords

Acute graft versus host disease; Reduced intensity cord blood transplantation; Tacrolimus

Indexed keywords

ACICLOVIR; COTRIMOXAZOLE; FLUCONAZOLE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHYLPREDNISOLONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CHIMERA; CLINICAL ARTICLE; CONTINUOUS INFUSION; CORD BLOOD STEM CELL TRANSPLANTATION; CREATININE BLOOD LEVEL; DIABETES MELLITUS; ENCEPHALITIS; ENGRAFTMENT; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; MALE; MICROANGIOPATHY; MORTALITY; NEUROTOXICITY; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; REDUCED INTENSITY CONDITIONING; SEPSIS; SIDE EFFECT; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ACUTE DISEASE; ADULT; AGED; CORD BLOOD STEM CELL TRANSPLANTATION; CYCLOSPORINE; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROGNOSIS; TACROLIMUS;

EID: 34547913431     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000269796.23593.16     Document Type: Article

References (35)

1. Sanz GF, Saavedra S, Planelles D, et al. Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies. Blood 2001; 98: 2332.
2. Goggins TF, Rizzieri DR. Nonmyeloablative allogeneic stem cell transplantation using alternative donors. Cancer Control 2004; 11: 86.
3. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351: 2276.
4. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351: 2265.
5. Takahashi S, Iseki T, Ooi J, et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 2004; 104: 3813.
6. Narimatsu H, Terakura S, Matsuo K, et al. Short-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adults. Bone Marrow Transplant 2007; 39: 31.
7. Miyakoshi S, Yuji K, Kami M, et al. Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases. Clin Cancer Res 2004; 10: 3586.
8. Barker JN, Weisdorf DJ, DeFor TE, et al. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 2003; 102: 1915.
9. Narimatsu H, Kami M, Hara S, et al. Intestinal thrombotic microangiopathy following reduced-intensity umbilical cord blood transplantation. Bone Marrow Transplant 2005; 36: 517.
10. Narimatsu H, Matsumura T, Kami M, et al. Bloodstream infection after umbilical cord blood transplantation using reduced-intensity stem cell transplantation for adult patients. Biol Blood Marrow Transplant 2005; 11: 429.
11. Maeda T, Kusumi E, Kami M, et al. Disseminated tuberculosis following reduced-intensity cord blood transplantation for adult patients with hematological diseases. Bone Marrow Transplant 2005; 35: 91.
12. Nishihira H, Kato K, Isoyama K, et al. The Japanese cord blood bank network experience with cord blood transplantation from unrelated donors for haematological malignancies: An evaluation of graft-versus-host disease prophylaxis. Br J Haematol 2003; 120: 516.
13. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730.
14. Thiede C, Florek M, Bornhauser M, et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 1999; 23: 1055.
15. Narimatsu H, Kami M, Miyakoshi S, et al. Graft failure following reduced-intensity cord blood transplantation for adult patients. Br J Haematol 2006; 132: 36.
16. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825.
17. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250.
18. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: Initial treatment. Blood 1990; 76: 1464.
19. Bearman S, Appelbaum FR, Buckner C, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562.
20. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176.
21. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999; 18: 695.
22. Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 1997; 337: 373.
23. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998; 339: 1565.
24. Kurtzberg J, Laughlin M, Graham ML, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996; 335: 157.
25. Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 2001; 344: 1815.
26. Long GD, Laughlin M, Madan B, et al. Unrelated umbilical cord blood transplantation in adult patients. Biol Blood Marrow Transplant 2003; 9: 772.
27. Ooi J, Iseki T, Takahashi S, et al. Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome. Blood 2003; 101: 4711.
28. Ooi J, Iseki T, Takahashi S, et al. Unrelated cord blood transplantation for adult patients with de novo acute myeloid leukemia. Blood 2004; 103: 489.
29. Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062.
30. Hiraoka A, Ohashi Y, Okamoto S, et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001; 28: 181.
31. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92: 2303.
32. Kino T, Hatanaka H, Hashimoto M, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 1987; 40: 1249.
33. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555.
34. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64: 436.
35. Kusumi E, Kami M, Yuji K, et al. Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor. Bone Marrow Transplant 2004; 33: 697.